Table III.
Distribution of studies according to number of thyroid papillary carcinomas in the indeterminate or suspicious cytological samples and the number positive for BRAF mutation.
| First author (ref.) | Total of FNAs | Indeterminate or suspicious lesions / PTC number | Indeterminate or suspicious lesions / BRAF+ |
|---|---|---|---|
| Moses et al (43) | 196 | 137/33 (19 FVPTC) | 137/13 (3FVPTC) |
| Cantara et al (8) | 235 | 95/53 | 95/23 |
| Nikiforov et al (15) | 86 | 52/17 | 52/7 |
| Sapio et al (18) | 144 | 94/2 | 94/10 |
| Rowe et al (16) | 24 | 19/19 | 19/3 |
| Salvatore et al (17) | 96 | 34/15 (6 FVPTC) | 34/4 (1 FVPTC) |
| Xing et al (11) | 45 | 25/7 | 25/2 |
| Cohen et al (22) | 91 | 55/29 (21 FVPTC) | 55/5 (2 FVPTC) |
| Musholt et al (38) | 93 | 19/4 | 19/1 |
| Dujardin et al (36) | 25 | 13/7 | 13/4 |
| Kim et al (39) | 279 | 80/70 | 80/50 |
| Kwak et al (41) | 130 | 30/20 | 30/16 |
| Ohori et al (42) | 117 | 117/20 | 117/3 |
| Moon et al (30) | 91 | 91/84 | 91/42 |
| Marchetti et al (31) | 111 | 52/33 | 33/18 |
| Bentz et al (33) | 45 | 17/17 | 17/3 |
| Jo et al (34) | 101 | 24/9 | 24/7 |
| Pizzolanti et al (27) | 156 | 19/3 (1 FVPTC) | 19/2 (1FVPTC) |
| Sapio et al (28) | 132 | 37/6 | 37/4 |
| Chung et al (25) | 137 | 25/5 | 25/3 |
| Domingues et al (24) | 24 | 10/1 | 10/0 |
| Hayashida et al (13) | 21 | 1/1 | 1/1 |
| Yeo et al (45) | 209 | 63/49 (5 FVPTC) | 63/14 (3 FVPTC) |
| Adeniran et al (46) | 72 | 34/22 | 34/10 |
| Pelizzo et al (47) | 270 | 164/45 | 164/30 |
| Jin et al (26) | 71 | 12/(a) | 12/1 |
| Girlando et al (37) | 91 | 20/14 | 20/10 |
| Kim et al (29) | 103 | 27/18 (2 FVPTC) | 27/13 |
a
Not determined. FNA, fine-needle aspiration; PTC, papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma.